12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

Sareum, Hebei Medical University Biomedical Engineering Center deal

Sareum granted Hebei Medical University Biomedical Engineering Center (HMUBEC) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize Sareum's inhibitor of aurora kinases and FMS-like tyrosine kinase 3 (

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >